Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-<i>d</i>]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone

Paul A. BroughVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KXavier BarrilVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KJenifer BorgognoniVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KPatrick ChêneNovartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, SwitzerlandNicholas G. DaviesVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KBen DavisVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KMartin J. DrysdaleVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KBrian DymockVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KSuzanne A. EcclesCancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, U.KCarlos Garcı́a-Echeverrı́aNovartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, SwitzerlandChristophe FromontVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KAngela HayesCancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, U.KRoderick E. HubbardVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KAllan M. JordanVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KMichael Rugaard JensenNovartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, SwitzerlandAndrew J. MasseyVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KAngela MerrettVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KAntony PadfieldVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KRachel ParsonsVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KThomas RadimerskiNovartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, SwitzerlandFlorence I. RaynaudCancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, U.KAlan RobertsonVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KStephen D. RoughleyVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KJoseph SchoepferNovartis Institutes for Biomedical Research, Novartis Pharma AG, CH-4002 Basel, SwitzerlandHeather SimmoniteVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KSwee Y. SharpCancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, U.KA.E. SurgenorVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KMelanie ValentiCancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, U.KSteven B. WallsVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KPaul WebbVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KMike WoodVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.KPaul WorkmanCancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, U.KLisa WrightVernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.K
2009en
ABI

Аннотация

Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe novel 2-aminothieno[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors, which were designed by combining structural elements of distinct low affinity hits generated from fragment-based and in silico screening exercises in concert with structural information from X-ray protein crystallography. Examples from this series have high affinity (IC50 = 50-100 nM) for Hsp90 as measured in a fluorescence polarization (FP) competitive binding assay and are active in human cancer cell lines where they inhibit cell proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Several examples (34a, 34d and 34i) caused tumor growth regression at well tolerated doses when administered orally in a human BT474 human breast cancer xenograft model.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0